Company: FVN
Filing Date: 2025-04-14
Form Type: DRS/A
Source: 0001829126-25-002616
Chunk: 161

Company: Future Vision II Acquisition Corp.
Filing Date: 2025-04-14
Form: DRS/A
Chunk 161
---
 align='center'>88</div>

New VIWO may be subject to securities litigation, which is expensive and could divert management attention.

The market price of New VIWO’s ordinary shares may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. New VIWO may be the target of this type of litigation in the future. Securities litigation against New VIWO could result in substantial costs and divert management’s attention from other business concerns, which could seriously harm New VIWO’s business.

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about New VIWO or its business, its ordinary shares price and trading volume could decline.

The trading market for New VIWO’s ordinary shares will depend in part on the research and reports that securities or industry analysts publish about New VIWO or its business. Securities and industry analysts do not currently, and may never, publish research on New VIWO. If no securities or industry analysts commence coverage of New VIWO, the trading price for its ordinary shares would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover New VIWO downgrade its securities or publish inaccurate or unfavorable research about its business, its stock price would likely decline. If one or more of these analysts cease coverage of New VIWO or fail to publish reports on New VIWO, demand for its ordinary shares could decrease, which might cause its ordinary share price and trading volume to decline.

If New VIWO cannot satisfy, or continue to satisfy, the initial listing requirements and other rules of Nasdaq, New VIWO’s securities may not be listed or may be delisted, which could negatively impact the price of its securities and your ability to sell them.

New VIWO will seek to have its securities approved for listing on the Nasdaq Capital Market. New VIWO cannot assure you that it will be able to meet the initial listing requirement including shareholders’ equity, minimum share price, minimum market value of publicly held shares, 300 round lot shareholders and various additional requirements in order to obtain approval to list on the Nasdaq Capital Market. Even if New VIWO’s securities are listed on Nasdaq, it cannot assure you that its securities will continue to be listed on Nasdaq.

In addition, in order to maintain its listing on Nasdaq, New VIWO will be required to comply with certain rules of Nasdaq, including those regarding minimum shareholders’ equity, minimum share price, minimum market